EyePoint Pharmaceuticals Inc (STU:PV3B)
€ 7.012 0.01 (0.14%) Market Cap: 382.82 Mil Enterprise Value: 152.78 Mil PE Ratio: 0 PB Ratio: 1.83 GF Score: 59/100

EyePoint Pharmaceuticals Inc Conference call to discuss topline results Transcript

Dec 04, 2023 / 01:00PM GMT
Release Date Price: €17.5 (+212.50%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to DAVIO 2 top-line data conference call. (Operator Instructions) Please be advised that today's conference is being recorded.

I would like now to turn the conference over to EyePoint Pharmaceuticals President and Chief Executive Officer, Dr. Jay Duker. Please go ahead.

Jay Duker
EyePoint Pharmaceuticals, Inc. - President, CEO, & Board Director

Thank you very much, and good morning, everybody. With me this morning is George Elston, our Executive Vice President and CFO. We really appreciate you joining us for this really exciting data release of our DAVIO 2 Phase 2 clinical trial top-line results.

As we may be making forward-looking statements, we need to remind you of that. And if you would like more details around the forward-looking statements, you can visit our website.

EyePoint Pharmaceuticals is a company that's dedicated to improving the lives of patients by sustained delivery of medications to the back of the eye. Our lead asset, which you are going to hear about

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot